Article
Novel antibody cocktail therapy targeting extracellular tumor-specific mutations to treat EMT6 cell line-derived triple-negative breast cancer.
Scientific reports - 6 Apr 2026
Pero Stephanie C, Shukla Girja S, Sun Yujing, Barrantes-Reynolds Ramiro, Hartman Colin J, Ackerman Margaret E, Mei Linda, Zhang Fan, Fournier Matthew R, Krag David N
Abstract excerpt
Treatment options for triple-negative breast cancer (TNBC) remain limited, and the highly heterogeneous nature of these tumors often contributes to therapeutic resistance. While we have previously demonstrated that antibodies targeting multiple distinct mutated cell surface proteins (MSPs) unique to a given tumor can disrupt tumor growth in mice, the feasibility of this approach in TNBC remains uncertain. Here,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.